Reinfection rate and endoscopic changes after successful eradication of Helicobacter pylori

Table 1 Recurrence of Helicobacter pylori (H. pylori) after successful eradication therapy n (%)

Follow up period	n	Recurrence
1 ≤ yr < 2	186	14 (7.5)
2 ≤ yr < 3	133	15 (11.3)
3 ≤ yr < 4	90	8 (8.9)
4 ≤ yr < 5	62	8 (12.9)
5 ≤ yr < 6	40	3 (7.5)
6 ≤ yr < 7	27	6 (22.2)
7 ≤ yr < 8	13	2 (15.4)
8 ≤ yr < 9	7	2 (28.5)
9 ≤ yr < 10	1	0 (0.0)
Total		58 (31.2)

Table 2 Recurrence rate according to the H. pylori eradication regimen n (%)

Therapeutic regimens	n	Recurrence
Omeprazole + clarithromycin + amoxicillin	137	41 (30.0)
Bismuth subcitrate + ranitidine + metronidazole + amoxicillin	39	14 (35.9)
Omeprazole + bismuth subcitrate + metronidazole + tetracycline	10	3 (30.0)

Table 3 Comparisons between the H. pylori-cured and -recurred group (mean ± SD) n (%)

	Cured group (n = 128)	Recurred group (n = 58)	P
Age (yr)	49.4 ± 11.2	51.5 ± 11.9	NS
Male:Female	65:63	33:23	NS
Follow up (mo)	40.6 ± 24.3	42.5 ± 23.7	NS
Endoscopic findings
Reflux esophagitis
Presence at initial investigation	19 (15.0)	3 (5.2)	NS
Newly developed or aggravated at follow up	25 (19.7)	8 (13.8)	NS
Improved at follow up	9 (7.1)	3 (5.2)	NS
Atrophic gastritis
Presence at initial investigation	11 (8.7)	8 (13.8)	NS
Newly developed or aggravated at follow up	7 (5.5)	2 (3.4)	NS
Improved at follow up	3 (2.4)	1 (1.7)	NS
Metaplastic gastritis
Presence at initial investigation	12 (9.4)	4 (6.9)	NS
Newly developed or aggravated at follow up	5 (3.9)	2 (3.4)	NS
Improved at follow up	7 (5.5)	2 (3.4)	NS

NS: Not significant.